var data={"title":"Nontuberculous mycobacterial pulmonary infections in children","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Nontuberculous mycobacterial pulmonary infections in children</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/contributors\" class=\"contributor contributor_credentials\">Andrea T Cruz, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/contributors\" class=\"contributor contributor_credentials\">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/contributors\" class=\"contributor contributor_credentials\">Mary M Torchia, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 29, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1060354616\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nontuberculous mycobacteria (NTM) are a miscellaneous collection of acid-fast bacteria that are widespread in the environment [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/1\" class=\"abstract_t\">1</a>]. They have been isolated from numerous environmental sources including water, soil, food products, and domestic and wild animals [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"abstract_t\">2</a>]. Health care-associated transmission has occurred with medical equipment [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/3-5\" class=\"abstract_t\">3-5</a>].</p><p>More than 130 species of have been identified, not all of which have been documented to cause disease in humans [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/6-9\" class=\"abstract_t\">6-9</a>]. NTM pathogens are classified as rapidly growing or slowly growing (<a href=\"image.htm?imageKey=ID%2F61936\" class=\"graphic graphic_table graphicRef61936 \">table 1</a>). Rapidly growing species grow within seven days and include <em>Mycobacterium fortuitum</em>, <em>Mycobacterium abscessus</em>, and <em>Mycobacterium</em> <em>chelonae</em>. Slowly growing species require several weeks to grow and include <em>Mycobacterium avium</em> complex (MAC),<em> Mycobacterium marinum</em>, and<em> Mycobacterium</em> <em>kansasii</em>. (See <a href=\"topic.htm?path=microbiology-of-nontuberculous-mycobacteria#H2\" class=\"medical medical_review\">&quot;Microbiology of nontuberculous mycobacteria&quot;, section on 'Classification'</a>.)</p><p>NTM can cause a broad range of infections that vary depending on the particular NTM species and the host. In children, NTM cause four main clinical syndromes: lymphadenopathy, skin and soft tissue infection (SSTI), pulmonary disease (predominantly in children with underlying pulmonary conditions), and disseminated disease (predominantly in immune-compromised children).</p><p>This topic will provide an overview of NTM pulmonary infections in children. NTM lymphadenitis, SSTI, disseminated infection, and bacteremia in children are discussed separately. (See <a href=\"topic.htm?path=nontuberculous-mycobacterial-lymphadenitis-in-children\" class=\"medical medical_review\">&quot;Nontuberculous mycobacterial lymphadenitis in children&quot;</a> and <a href=\"topic.htm?path=nontuberculous-mycobacterial-skin-and-soft-tissue-infections-in-children\" class=\"medical medical_review\">&quot;Nontuberculous mycobacterial skin and soft tissue infections in children&quot;</a> and <a href=\"topic.htm?path=disseminated-nontuberculous-mycobacterial-ntm-infections-and-ntm-bacteremia-in-children\" class=\"medical medical_review\">&quot;Disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1060354623\"><span class=\"h1\">MICROBIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most common NTM species causing pulmonary disease in adults in the United States are <em>M. avium</em> complex (MAC, <em>M. avium</em> and <em>Mycobacterium</em> <em>intracellulare</em>), <em>M. abscessus</em>, and<em> M. kansasii</em> [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/10\" class=\"abstract_t\">10</a>]. Few data are available for children. However, MAC and <em>M. abscessus</em> are the species most frequently isolated from children with cystic fibrosis [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/11-16\" class=\"abstract_t\">11-16</a>]. In one series of 17 children with NTM pulmonary disease, MAC was more common in previously healthy children (n = 5) and <em>M. abscessus </em>or<em> M. chelonae </em>in children with cystic fibrosis (n = 8) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/17\" class=\"abstract_t\">17</a>].</p><p class=\"headingAnchor\" id=\"H1060354630\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Estimates of the true burden of NTM infections in children are unavailable, in part because NTM infections may be asymptomatic and because NTM infections are not communicable; reporting of NTM infections is not required in the United States or many other countries [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"abstract_t\">2</a>]. The overall prevalence of NTM disease appears to be increasing with time (possibly as a result of enhanced detection) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/18-22\" class=\"abstract_t\">18-22</a>]. (See <a href=\"topic.htm?path=epidemiology-of-nontuberculous-mycobacterial-infections\" class=\"medical medical_review\">&quot;Epidemiology of nontuberculous mycobacterial infections&quot;</a>.)</p><p>In case series, the prevalence of NTM among respiratory specimens from patients with cystic fibrosis ranges from 4 to 20 percent [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2,11,14,23\" class=\"abstract_t\">2,11,14,23</a>]. However, isolation of NTM from a respiratory specimen does not necessarily indicate NTM disease. In a prospective study of 682 sputum specimens from 106 children with cystic fibrosis, NTM were isolated from 6.6 percent, but only 1.9 percent had NTM disease (ie, clinical and functional decline in addition to isolation) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/23\" class=\"abstract_t\">23</a>]. Among patients with cystic fibrosis, NTM isolation is more common in teenagers and young adults than in younger patients [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/11-13,15,23\" class=\"abstract_t\">11-13,15,23</a>].</p><p>NTM is transmitted through environmental sources. They are ubiquitous in the environment and have been isolated from water, soil, food products, and domestic and wild animals [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"abstract_t\">2</a>]. An observational study found near-identical isolates of <em>M. abscessus</em> in cystic fibrosis clinics, suggesting the possibility of person-to-person transmission [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/16\" class=\"abstract_t\">16</a>]. The respiratory or gastrointestinal tract is the usual portal of entry for NTM pulmonary disease. The incubation period is variable [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/9\" class=\"abstract_t\">9</a>].</p><p class=\"headingAnchor\" id=\"H1060354637\"><span class=\"h1\">RISK FACTORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cystic fibrosis is the most common risk factor for pulmonary NTM disease in children in industrialized nations [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/15,24\" class=\"abstract_t\">15,24</a>]. Screening patients with cystic fibrosis to make sure that NTM cultures are negative before initiation of anti-inflammatory therapy with a macrolide antibiotic is discussed separately. (See <a href=\"topic.htm?path=cystic-fibrosis-overview-of-the-treatment-of-lung-disease#H12\" class=\"medical medical_review\">&quot;Cystic fibrosis: Overview of the treatment of lung disease&quot;, section on 'Macrolide antibiotics'</a>.)</p><p>Other risk factors for NTM pulmonary disease include polymorphisms in the cystic fibrosis transmembrane conductance regulatory genes without classic cystic fibrosis, polymorphisms in the natural resistance-associated macrophage protein 1 (<em>NRAMP1</em>) gene, hematopoietic stem cell transplantation, and congenital defects in interferon gamma and interleukin (IL)-12 synthesis and response pathways [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/25-32\" class=\"abstract_t\">25-32</a>]. While children with severe combined immunodeficiency, DiGeorge syndrome, chronic granulomatous disease, and hyperimmunoglobulin M syndrome also have defects in portions of the IL-12 pathway, they are not prone to disseminated infection with NTM species [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/33\" class=\"abstract_t\">33</a>]. (See <a href=\"topic.htm?path=mendelian-susceptibility-to-mycobacterial-diseases-specific-defects\" class=\"medical medical_review\">&quot;Mendelian susceptibility to mycobacterial diseases: Specific defects&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1060354644\"><span class=\"h1\">CLINICAL FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinically significant NTM pulmonary disease is most often described in children with preexisting lung disease (eg, cystic fibrosis) and non-human immunodeficiency virus (HIV) immune deficiency and disseminated NTM disease; it is less common in patients with HIV infection and disseminated NTM disease [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/34,35\" class=\"abstract_t\">34,35</a>]. (See <a href=\"topic.htm?path=disseminated-nontuberculous-mycobacterial-ntm-infections-and-ntm-bacteremia-in-children#H1060363832\" class=\"medical medical_review\">&quot;Disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children&quot;, section on 'Risk factors'</a>.)</p><p>The clinical features of NTM pulmonary disease are variable and nonspecific [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"abstract_t\">2</a>]. Most patients have chronic or recurrent cough [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/36\" class=\"abstract_t\">36</a>]. Other pulmonary symptoms and signs include increased sputum production, dyspnea, hemoptysis, chest pain, rhonchi, crackles, wheezing, and stridor. Constitutional findings may include fever, fatigue, malaise, and weight loss; constitutional symptoms are more prevalent in immune-deficient children and children with advanced disease [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/36,37\" class=\"abstract_t\">36,37</a>].</p><p>The clinical features of NTM pulmonary disease may depend, to some extent, upon the underlying medical problem(s).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a review of 43 children (both healthy and with medical comorbidities) with NTM pulmonary disease, 60 percent had constitutional symptoms; fever was the most common, followed by weight loss and fatigue [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/38\" class=\"abstract_t\">38</a>]. Night sweats were uncommon.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among children with underlying lung disease, worsening of existing pulmonary symptoms (cough, increased sputum production, exercise intolerance, decline in pulmonary function), worsening nutritional status, or low-grade fever may be a clue pulmonary NTM disease. In patients with cystic fibrosis, chronic NTM infection is associated with worsening pulmonary function [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/39\" class=\"abstract_t\">39</a>].</p><p/><p class=\"bulletIndent1\">The clinical manifestations of pulmonary disease in patients with cystic fibrosis (including disease due to infection) are discussed separately. (See <a href=\"topic.htm?path=cystic-fibrosis-clinical-manifestations-of-pulmonary-disease\" class=\"medical medical_review\">&quot;Cystic fibrosis: Clinical manifestations of pulmonary disease&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In two case series, each including five children without underlying lung disease who developed culture-positive NTM pulmonary disease, the most common symptoms were wheezing or stridor that did not respond to bronchodilator or glucocorticoid therapy [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/40,41\" class=\"abstract_t\">40,41</a>]. All of the children were noted to have endobronchial lesions, including granulomas, <span class=\"nowrap\">and/or</span> hilar lymphadenopathy.</p><p/><p class=\"headingAnchor\" id=\"H1060354651\"><span class=\"h1\">RADIOGRAPHIC FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Imaging of the chest is necessary to diagnose NTM pulmonary disease [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"abstract_t\">2</a>]. Radiographic findings in NTM pulmonary disease include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nodular or cavitary opacities on chest radiograph</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multifocal bronchiectasis with multiple small nodules on high-resolution computed tomography (<a href=\"image.htm?imageKey=PEDS%2F86444\" class=\"graphic graphic_diagnosticimage graphicRef86444 \">image 1</a>)</p><p/><p>Radiographic features of NTM pulmonary disease may vary depending upon the underlying medical problem(s). The most common radiographic findings in otherwise healthy children include hilar lymphadenopathy and a tree-in-bud appearance associated with endobronchial spread [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/40\" class=\"abstract_t\">40</a>]. Infiltrates are more likely in children with constitutional symptoms [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/38\" class=\"abstract_t\">38</a>]. Pleural effusions are uncommon, and cavitary lesions in young children are rare.</p><p>Radiographic features of NTM pulmonary disease also may vary depending on the causative species [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"abstract_t\">2</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>M. avium </em>complex (MAC) &ndash; Apical fibrocavitary disease or nodular and interstitial nodular infiltrates often involving the right middle lobe or lingula</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>M. kansasii</em> &ndash; Cavitary infiltrates in the upper lobes</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>M. abscessus</em> &ndash; Multilobar, patchy, reticulonodular or mixed interstitial-alveolar opacities with an upper lobe predominance; cavitation may occur</p><p/><p class=\"headingAnchor\" id=\"H1326135742\"><span class=\"h1\">DIAGNOSIS</span></p><p class=\"headingAnchor\" id=\"H1762312726\"><span class=\"h2\">Diagnostic criteria</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of NTM pulmonary disease is established based on the combination of compatible clinical and radiographic findings, the isolation of an NTM species in culture, and exclusion of other conditions in the differential diagnosis [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"abstract_t\">2</a>]. (See <a href=\"#H1060354665\" class=\"local\">'Differential diagnosis'</a> below.)</p><p>We agree with the American Thoracic Society and Infectious Disease Society of America <span class=\"nowrap\">(ATS/IDSA)</span> criteria for the diagnosis of NTM pulmonary disease (<a href=\"image.htm?imageKey=ID%2F61404\" class=\"graphic graphic_table graphicRef61404 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"abstract_t\">2</a>]. Both the clinical and microbiologic criteria must be fulfilled.</p><p>When NTM is isolated from a patient with underlying lung disease, it can be difficult to determine whether NTM represents a true pathogen, colonization, or a contaminant. Consultation with an expert in infectious diseases <span class=\"nowrap\">and/or</span> pulmonary medicine may be necessary. (See <a href=\"topic.htm?path=diagnosis-of-nontuberculous-mycobacterial-infections-of-the-lungs-in-hiv-negative-patients\" class=\"medical medical_review\">&quot;Diagnosis of nontuberculous mycobacterial infections of the lungs in HIV-negative patients&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1326135601\"><span class=\"h3\">Clinical suspicion</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>NTM pulmonary disease may be suspected in [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2,24,40\" class=\"abstract_t\">2,24,40</a>] (see <a href=\"#H1060354644\" class=\"local\">'Clinical features'</a> above):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Children with underlying pulmonary disease with worsening of pulmonary <span class=\"nowrap\">symptoms/function,</span> weight loss, or low-grade fever, in whom other causes have been excluded</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Children with cystic fibrosis and exacerbation of pulmonary symptoms that does not respond to routine treatment and antipseudomonal antibiotics (see <a href=\"topic.htm?path=cystic-fibrosis-overview-of-the-treatment-of-lung-disease\" class=\"medical medical_review\">&quot;Cystic fibrosis: Overview of the treatment of lung disease&quot;</a> and <a href=\"topic.htm?path=cystic-fibrosis-antibiotic-therapy-for-chronic-pulmonary-infection\" class=\"medical medical_review\">&quot;Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Children with non-human immunodeficiency virus (HIV) immune deficiency and disseminated NTM disease</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Previously healthy children with wheezing or stridor that is unresponsive to bronchodilator or glucocorticoid therapy</p><p/><p class=\"headingAnchor\" id=\"H1923504671\"><span class=\"h3\">Imaging studies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Radiographic findings in NTM pulmonary disease include [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"abstract_t\">2</a>] (see <a href=\"#H1060354651\" class=\"local\">'Radiographic features'</a> above):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nodular or cavitary opacities on chest radiograph, or</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multifocal bronchiectasis with multiple small nodules on high-resolution computed tomography (<a href=\"image.htm?imageKey=PEDS%2F86444\" class=\"graphic graphic_diagnosticimage graphicRef86444 \">image 1</a>)</p><p/><p>In children with underlying pulmonary disease, it is important to compare radiographs and computed tomography findings with previous studies to determine if there has been a change. It can be difficult to differentiate between worsening of the primary pulmonary disorder and NTM pulmonary disease.</p><p class=\"headingAnchor\" id=\"H1762312692\"><span class=\"h3\">Microbiologic testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>When NTM pulmonary disease is suspected, pulmonary specimens should be sent for histopathology, acid-fast bacillus (AFB) staining, and mycobacterial culture (as well as bacterial and fungal stains and cultures as clinically indicated).</p><p>It is helpful to discuss specimen collection, transport, and culture processing with the microbiology laboratory before sending tissue or fluid to the laboratory. Most NTM species will not grow in traditional bacterial culture media; rapidly growing NTM species (eg, <em>M. abscessus</em>) are an exception [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/42\" class=\"abstract_t\">42</a>]. Techniques for maximizing the yield of cultures are discussed separately. (See <a href=\"topic.htm?path=microbiology-of-nontuberculous-mycobacteria#H4\" class=\"medical medical_review\">&quot;Microbiology of nontuberculous mycobacteria&quot;, section on 'Culture'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>AFB staining</strong> &ndash; AFB staining cannot distinguish among NTM species or between NTM species and <em>Mycobacterium tuberculosis</em>. Negative AFB stains do not exclude a diagnosis of mycobacterial disease. In a prospective series of 104 positive NTM cultures from patients with cystic fibrosis, the AFB smear was positive only in one-third [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/11\" class=\"abstract_t\">11</a>]. Positive AFB stains increase the likelihood that an NTM isolate is clinically significant [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"abstract_t\">2</a>]. (See <a href=\"topic.htm?path=microbiology-of-nontuberculous-mycobacteria#H3\" class=\"medical medical_review\">&quot;Microbiology of nontuberculous mycobacteria&quot;, section on 'Microscopy'</a> and <a href=\"#H2118471755\" class=\"local\">'Clinical significance'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Culture</strong> &ndash; A positive NTM culture (from sputum, bronchial wash or lavage, transbronchial or other lung biopsy) in a patient with compatible clinical and radiographic findings establishes the diagnosis of NTM pulmonary disease (<a href=\"image.htm?imageKey=ID%2F61404\" class=\"graphic graphic_table graphicRef61404 \">table 2</a>). Identification of the NTM species is necessary to determine the clinical significance and appropriate antimycobacterial regimen.</p><p/><p class=\"bulletIndent1\">The importance of obtaining adequate specimens for culture and proper processing cannot be over-emphasized. The yield of cultures may be reduced by insufficient quality (eg, nasopharyngeal swab rather than expectorated sputum) or quantity of a respiratory specimen [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/43\" class=\"abstract_t\">43</a>]. (See <a href=\"topic.htm?path=microbiology-of-nontuberculous-mycobacteria#H4\" class=\"medical medical_review\">&quot;Microbiology of nontuberculous mycobacteria&quot;, section on 'Culture'</a>.)</p><p/><p class=\"bulletIndent1\">The time (in days) to detection of mycobacterial growth may help to distinguish between NTM species. <em>M. abscessus</em> grows within seven days, whereas <em>M. avium </em>complex (MAC) and <em>M. kansasii</em> require several weeks for growth.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Rapid diagnostic tests </strong>&ndash; Rapid methods for identification of NTM species include high-pressure liquid chromatography (HPLC) and polymerase chain reaction (PCR) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"abstract_t\">2</a>]. HPLC examines the mycolic acid fingerprint patterns that differ among most species or complexes of mycobacteria and can be used to speciate NTM, including rapidly growing mycobacteria [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/44\" class=\"abstract_t\">44</a>]. However, HPLC cannot reliably differentiate between <em>M. abscessus</em> and <em>M. chelonae</em>.</p><p/><p class=\"bulletIndent1\">Although PCR detection of genetic material cannot differentiate between colonization and infection, PCR may identify NTM species before identification in culture. Nucleic acid probes for MAC and <em>M. kansasii</em> are commercially available. However, there is little experience with PCR and other molecular modalities for the diagnosis of NTM pulmonary disease in children. In adult patients, real-time multiplex PCR is increasingly used to differentiate between <em>M. tuberculosis</em> and NTM species such as MAC and <em>M. abscessus </em>[<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/45\" class=\"abstract_t\">45</a>].</p><p/><p class=\"headingAnchor\" id=\"H2118471755\"><span class=\"h3\">Clinical significance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>When NTM is isolated from a child with pulmonary symptoms and signs, the clinical significance of the isolate must be determined. The pathogenicity of the various NTM species varies substantially. The possibility that NTM was isolated as a result of contamination or represents colonization of diseased lung also must be considered [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"abstract_t\">2</a>]. Consultation with a specialist in infectious diseases may be helpful in determining the clinical significance of the isolate.</p><p>Factors that increase the likelihood of clinical significance include recovery from multiple specimens, recovery in large quantities (ie, AFB-positive specimens), and recovery from a normally sterile site [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H1060354665\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Important considerations in the differential diagnosis of NTM pulmonary disease in children include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Progression of primary pulmonary disease (eg, worsening bronchiectasis in patients with cystic fibrosis) &ndash; Progression of primary pulmonary disease is rarely associated with extrapulmonary manifestations, including bacteremia.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>M. tuberculosis</em> &ndash; The cavitary appearance and endobronchial spread of NTM can mimic radiographic findings of <em>M. tuberculosis</em>. It is important to distinguish tuberculous from NTM pulmonary disease because they require different treatments; in addition, <em>M. tuberculosis</em> requires contact tracing, whereas NTM does not.</p><p/><p class=\"bulletIndent1\">In a child with risk factors for <em>M. tuberculosis</em> and acid-fast bacillus-positive sputum, NTM and <em>M. tuberculosis</em> must be differentiated by mycobacterial culture and speciation. In a series of respiratory specimens from 17 children in Texas who met criteria for diagnosis of NTM pulmonary disease (<a href=\"image.htm?imageKey=ID%2F61404\" class=\"graphic graphic_table graphicRef61404 \">table 2</a>), <em>M. tuberculosis </em>was isolated more frequently than all other mycobacterial species (23 versus 17 specimens) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/17\" class=\"abstract_t\">17</a>].</p><p/><p class=\"bulletIndent1\">It may be necessary to initiate empiric therapy before the distinction between NTM and <em>M. tuberculosis</em> is made. In such cases, coverage for both pathogens is provided in a multidrug regimen. (See <a href=\"#H1326136013\" class=\"local\">'NTM and M. tuberculosis'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other forms of nodular lung disease, including disseminated fungal disease (<a href=\"image.htm?imageKey=ID%2F70568\" class=\"graphic graphic_table graphicRef70568 \">table 3</a>) &ndash; Clinical features (eg, exposures) may help to differentiate NTM from other nodular lung diseases, but microbiologic studies are necessary for definitive diagnosis.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Pneumocystis jirovecii</em> pneumonia &ndash; The ground-glass appearance occasionally seen in NTM pulmonary disease can mimic <em>P. jirovecii </em>pneumonia. Microbiologic studies can be helpful in differentiating between NTM and <em>P. jirovecii</em> pneumonia. (See <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-pneumocystis-pneumonia-in-hiv-uninfected-patients#H14\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in HIV-uninfected patients&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1060354672\"><span class=\"h1\">TREATMENT</span></p><p class=\"headingAnchor\" id=\"H1762312992\"><span class=\"h2\">General principles</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Given the side effect profile of the medications used to treat NTM pulmonary disease (<a href=\"image.htm?imageKey=PEDS%2F86161\" class=\"graphic graphic_table graphicRef86161 \">table 4</a>), it is essential to make sure that children meet the criteria for diagnosis (<a href=\"image.htm?imageKey=ID%2F61404\" class=\"graphic graphic_table graphicRef61404 \">table 2</a>) before initiating therapy.</p><p>Antimycobacterial treatment generally is warranted for children who meet clinical and microbiologic criteria for NTM pulmonary disease (<a href=\"image.htm?imageKey=ID%2F61404\" class=\"graphic graphic_table graphicRef61404 \">table 2</a>). However, the potential risks and benefits of antimycobacterial therapy disease must be considered before initiating treatment.</p><p>As an example, in an adolescent with cystic fibrosis who is awaiting lung transplantation in whom <em>M. abscessus</em> is isolated, the benefits of decreased burden of <em>M. abscessus</em> and potential decreased risk of recurrence posttransplant may outweigh the adverse effects of parenteral multidrug therapy with ototoxic and nephrotoxic drugs. On the other hand, the risks of therapy may outweigh the benefits in a young child in whom a potentially nonpathogenic species or contaminant (eg, <em>Mycobacterium mucogenicum</em>) is isolated from a respiratory specimen. (See <a href=\"#H1060354693\" class=\"local\">'M. abscessus'</a> below.)</p><p>Susceptibility testing is recommended for clinically significant NTM pulmonary isolates [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"abstract_t\">2</a>]. However, with the exception of macrolides in the treatment of <em>M. avium</em> complex (MAC), drug susceptibility testing for NTM has less correlation with in vivo response than for other pathogens.</p><p>Given that the diagnostic criteria for NTM pulmonary disease require sequential sputum samples (<a href=\"image.htm?imageKey=ID%2F61404\" class=\"graphic graphic_table graphicRef61404 \">table 2</a>), speciation and drug susceptibility results often are available before initiation of antimicrobial therapy [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"abstract_t\">2</a>]. However, it may be necessary to initiate empiric therapy before speciation is complete, particularly when <em>M. tuberculosis</em> cannot be excluded. (See <a href=\"#H1762312726\" class=\"local\">'Diagnostic criteria'</a> above and <a href=\"#H1060354665\" class=\"local\">'Differential diagnosis'</a> above.) </p><p class=\"headingAnchor\" id=\"H2118470656\"><span class=\"h2\">Antimycobacterial therapy</span></p><p class=\"headingAnchor\" id=\"H1326136013\"><span class=\"h3\">NTM and M. tuberculosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For children in whom the distinction between NTM and <em>M. tuberculosis</em> remains uncertain after clinical, radiographic, and initial laboratory evaluation (eg, children with risk factors for <em>M. tuberculosis</em> and positive smears for acid-fast bacilli [AFB]), we suggest empiric treatment with the following regimen until speciation is available (<a href=\"image.htm?imageKey=PEDS%2F86161\" class=\"graphic graphic_table graphicRef86161 \">table 4</a>) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/46\" class=\"abstract_t\">46</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=isoniazid-pediatric-drug-information\" class=\"drug drug_pediatric\">Isoniazid</a>, <strong>plus</strong></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=rifampin-rifampicin-pediatric-drug-information\" class=\"drug drug_pediatric\">Rifampin</a>, <strong>plus</strong></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ethambutol-pediatric-drug-information\" class=\"drug drug_pediatric\">Ethambutol</a>, <strong>plus</strong></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=pyrazinamide-pediatric-drug-information\" class=\"drug drug_pediatric\">Pyrazinamide</a>, <strong>plus</strong></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A macrolide (<a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a> or <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a>)</p><p/><p>We generally prefer <a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a> to <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a> for pulmonary NTM infection. Azithromycin can be administered once daily, which may increase adherence. In addition, there is the potential for drug interaction between clarithromycin and rifamycins &ndash; rifamycins can decrease the serum concentration of clarithromycin [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/47,48\" class=\"abstract_t\">47,48</a>]. It is unclear the degree to which the benefit of combination therapy is outweighed by the risk of selecting for clarithromycin resistance. However, use of azithromycin rather than clarithromycin permits combination therapy without potentially sacrificing the minimal inhibitory concentration for the macrolide. A 2016 systematic review found that there was no difference in the effectiveness of different antimicrobial regimens for NTM pulmonary infection in patients with cystic fibrosis [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/49\" class=\"abstract_t\">49</a>].</p><p>Based on in vitro susceptibilities, this regimen provides initial empiric coverage for <em>M. tuberculosis</em> and two NTM species frequently isolated from children with NTM pulmonary disease (MAC and <em>M. kansasii</em>). It is consistent with the recommendations of the American Thoracic <span class=\"nowrap\">Society/Infectious</span> Diseases Society of America <span class=\"nowrap\">(ATS/IDSA)</span> and the American Academy of Pediatrics (AAP) Committee on Infectious Diseases [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2,9\" class=\"abstract_t\">2,9</a>].</p><p>The regimen can be tailored according to speciation and susceptibility testing when these results are available. (See <a href=\"#H1762312692\" class=\"local\">'Microbiologic testing'</a> above.)</p><p class=\"headingAnchor\" id=\"H1060354686\"><span class=\"h3\">M. avium complex</span></p><p class=\"headingAnchor\" id=\"H1923504373\"><span class=\"h4\">HIV-negative children</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest that human immunodeficiency virus (HIV)-negative children with nodular or noncavitating bronchiectatic MAC lung disease be treated with a regimen that includes (<a href=\"image.htm?imageKey=PEDS%2F86161\" class=\"graphic graphic_table graphicRef86161 \">table 4</a>) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2,9\" class=\"abstract_t\">2,9</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A macrolide (<a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a> or <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a>), <strong>plus</strong></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ethambutol-pediatric-drug-information\" class=\"drug drug_pediatric\">Ethambutol</a>, <strong>plus</strong></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A rifamycin (<a href=\"topic.htm?path=rifampin-rifampicin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifampin</a> or <a href=\"topic.htm?path=rifabutin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifabutin</a>)</p><p/><p>We generally prefer <a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a> to <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a> for pulmonary NTM infection. (See <a href=\"#H1326136013\" class=\"local\">'NTM and M. tuberculosis'</a> above.)</p><p>The medications are administered three times per week until the sputum cultures have been negative for at least one year [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"abstract_t\">2</a>]. Three-times-weekly dosing for patients with nodular or nonsevere bronchiectatic MAC disease is supported by several prospective studies in adult patients demonstrating effectiveness [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/50-52\" class=\"abstract_t\">50-52</a>] and a systematic review demonstrating increased adherence [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/53\" class=\"abstract_t\">53</a>].</p><p>We suggest that HIV-negative children with extensive bronchiectasis or fibrocavitary MAC lung disease be treated with a regimen that includes (<a href=\"image.htm?imageKey=PEDS%2F86161\" class=\"graphic graphic_table graphicRef86161 \">table 4</a>) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2,9\" class=\"abstract_t\">2,9</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A macrolide (<a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a> or <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a>), <strong>plus</strong></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ethambutol-pediatric-drug-information\" class=\"drug drug_pediatric\">Ethambutol</a>, <strong>plus</strong></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A rifamycin (<a href=\"topic.htm?path=rifampin-rifampicin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifampin</a> or <a href=\"topic.htm?path=rifabutin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifabutin</a>), <strong>plus</strong></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An aminoglycoside (<a href=\"topic.htm?path=amikacin-pediatric-drug-information\" class=\"drug drug_pediatric\">amikacin</a> or <a href=\"topic.htm?path=streptomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">streptomycin</a>)</p><p/><p>For the macrolide, we generally prefer <a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a> to <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a>. The first three drugs should be administered daily. The aminoglycoside is also administered daily in children; however, in older adolescents, <a href=\"topic.htm?path=amikacin-pediatric-drug-information\" class=\"drug drug_pediatric\">amikacin</a> may be administered three times per week. In a randomized study in adult patients with tuberculous or nontuberculous mycobacterial infections, the administration of amikacin 25 <span class=\"nowrap\">mg/kg</span> three times per week was not associated with increased toxicity compared with daily dosing [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/54\" class=\"abstract_t\">54</a>]. The aminoglycoside should be discontinued after eight weeks; the remainder of the drugs should be continued until the child's sputum cultures have been negative for at least one year [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"abstract_t\">2</a>].</p><p>The recommendations for treatment of MAC pulmonary disease in HIV-negative children are based upon in vitro susceptibilities and observational studies in HIV-negative adult patients, in which multidrug treatment with a macrolide-containing regimen was associated with clearance of MAC from sputum in &gt;60 percent of patients [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/50,55,56\" class=\"abstract_t\">50,55,56</a>]. They are consistent with the recommendations of the <span class=\"nowrap\">ATS/IDSA</span> and the AAP Committee on Infectious Diseases [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2,9\" class=\"abstract_t\">2,9</a>].</p><p class=\"headingAnchor\" id=\"H1923504380\"><span class=\"h4\">HIV-positive children</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Respiratory symptoms are uncommon among HIV-infected children with disseminated MAC, and isolated pulmonary disease is rare [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/35\" class=\"abstract_t\">35</a>]. We suggest that children with HIV infections and MAC who meet the diagnostic criteria for pulmonary disease (<a href=\"image.htm?imageKey=ID%2F61404\" class=\"graphic graphic_table graphicRef61404 \">table 2</a>) be treated in the same manner as those with disseminated infection. (See <a href=\"topic.htm?path=disseminated-nontuberculous-mycobacterial-ntm-infections-and-ntm-bacteremia-in-children#H1590632073\" class=\"medical medical_review\">&quot;Disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children&quot;, section on 'Antimycobacterial therapy'</a>.)</p><p class=\"headingAnchor\" id=\"H1060354693\"><span class=\"h3\">M. abscessus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For children with <em>M. abscessus</em> pulmonary disease, we suggest initial treatment with (<a href=\"image.htm?imageKey=PEDS%2F86161\" class=\"graphic graphic_table graphicRef86161 \">table 4</a>) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/9\" class=\"abstract_t\">9</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A macrolide (<a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a> or <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a>), <strong>plus</strong></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=amikacin-pediatric-drug-information\" class=\"drug drug_pediatric\">Amikacin</a>, <strong>plus</strong></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=cefoxitin-pediatric-drug-information\" class=\"drug drug_pediatric\">Cefoxitin</a> or a carbapenem (eg, <a href=\"topic.htm?path=meropenem-pediatric-drug-information\" class=\"drug drug_pediatric\">meropenem</a>)</p><p/><p>The initial regimen should include three drugs to which there is documented susceptibility, bearing in mind that in vitro susceptibilities may not correlate with clinical response [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"abstract_t\">2</a>]. For children with substantial antibiotic exposures, it may not be possible to find three antibiotics to which the isolate has documented susceptibility. When this occurs, although there is little evidence for guidance, we start with the agent(s) to which <em>M. abscessus</em> is apparently susceptible and then add one or more bactericidal agents, trying to choose those with the fewest adverse effects and the most convenient dosing regimens (eg, oral rather than parenteral medications).</p><p>While both <a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a> and <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a> have been used to treat <em>M. abscessus</em> lung disease, we prefer azithromycin for several reasons: decreased drug-drug interactions, increased palatability of the liquid formulation, and an observational study suggesting that sustained culture conversion was more common in adults with <em>M. abscessus </em>lung disease who received azithromycin than in those who received clarithromycin [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/57\" class=\"abstract_t\">57</a>]. While <em>M. abscessus</em> is often considered as a single entity, there are three to four subspecies, at least two of which (<em>M. abscessus </em>T28 and <em>M. abscessus bolletii</em>) have inducible clarithromycin resistance, but resistance to other antibiotics remains consistent across the subspecies [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/58\" class=\"abstract_t\">58</a>].</p><p>The goal of <em>M. abscessus</em> therapy should not be microbiologic eradication. Instead, symptomatic and radiographic improvements should be the endpoints of therapy. In addition to the difficulty in eradicating <em>M. abscessus</em>, it is possible for patients to be reinfected by different <em>M. abscessus</em> genotypes during or after completion of antimicrobial therapy [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/59\" class=\"abstract_t\">59</a>]. In a retrospective review of adult patients with <em>M. abscessus</em> lung disease, &gt;40 percent relapsed within a year of treatment cessation; AFB sputum smear positivity was the only consistent predictor of treatment outcome [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/59\" class=\"abstract_t\">59</a>]. In another study, lower body mass index, bilateral lung involvement, and fibrocavitary disease were associated with poor prognoses [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/57\" class=\"abstract_t\">57</a>].</p><p>Although initial therapy should include three drugs to which there is documented susceptibility, after four to eight weeks of intensification therapy, two drugs may be used to complete therapy (usually for a total duration of 6 to 12 months). The duration of therapy may be limited by the patient's ability to tolerate the medications [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"abstract_t\">2</a>]. <em>M. abscessus</em> has a predilection for infecting diseased lungs and is difficult to eradicate; cure is generally possible only with surgical resection when lung disease is limited [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/36\" class=\"abstract_t\">36</a>]. (See <a href=\"#H1060354714\" class=\"local\">'Surgical therapy'</a> below.)</p><p><a href=\"topic.htm?path=linezolid-pediatric-drug-information\" class=\"drug drug_pediatric\">Linezolid</a> and fluoroquinolones can been used for patients with refractory <em>M. abscessus</em> pulmonary disease. However, the utility of linezolid in children may be limited by bone marrow suppression or optic neuritis, and high rates of fluoroquinolone resistance have been reported in children with no previous exposure [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/17\" class=\"abstract_t\">17</a>].</p><p class=\"headingAnchor\" id=\"H1060354707\"><span class=\"h3\">M. kansasii</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest that children with <strong>rifampin-susceptible</strong> <em>M. kansasii</em> pulmonary disease be treated with (<a href=\"image.htm?imageKey=PEDS%2F86161\" class=\"graphic graphic_table graphicRef86161 \">table 4</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=isoniazid-pediatric-drug-information\" class=\"drug drug_pediatric\">Isoniazid</a>, <strong>plus</strong></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=rifampin-rifampicin-pediatric-drug-information\" class=\"drug drug_pediatric\">Rifampin</a>, <strong>plus</strong></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ethambutol-pediatric-drug-information\" class=\"drug drug_pediatric\">Ethambutol</a>, <strong>plus</strong></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A macrolide (<a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a> or <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a>)</p><p/><p>We generally prefer <a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a> to <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a> for pulmonary NTM infection. (See <a href=\"#H1326136013\" class=\"local\">'NTM and M. tuberculosis'</a> above.)</p><p>Treatment for rifampin-susceptible <em>M. kansasii</em> should continue until sputum cultures have been negative for at least one year [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"abstract_t\">2</a>].</p><p>We suggest that children with <strong>rifampin-resistant</strong> isolates be treated with three drugs based upon in vitro susceptibilities. Potential agents include macrolides, fluoroquinolones, aminoglycosides, and <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information\" class=\"drug drug_pediatric\">trimethoprim-sulfamethoxazole</a> (TMP-SMX) (<a href=\"image.htm?imageKey=PEDS%2F86161\" class=\"graphic graphic_table graphicRef86161 \">table 4</a>). Treatment for rifampin-resistant <em>M. kansasii</em> should continue until sputum cultures have been negative for 12 to 18 months [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"abstract_t\">2</a>].</p><p>There have been no randomized trials of treatment for <em>M. kansasii</em>. In in vitro studies, <em>M. kansa</em>sii is susceptible to <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a>, TMP-SMX, <a href=\"topic.htm?path=amikacin-pediatric-drug-information\" class=\"drug drug_pediatric\">amikacin</a>, fluoroquinolones, and <a href=\"topic.htm?path=rifabutin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifabutin</a> [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/60-63\" class=\"abstract_t\">60-63</a>]. In observational studies, multidrug regimens that included <a href=\"topic.htm?path=rifampin-rifampicin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifampin</a> were associated with clearance of <em>M. kansasii</em> within four months in all patients [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/64-67\" class=\"abstract_t\">64-67</a>]. Relapse, which was rare, was associated with development of rifampin resistance [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/64\" class=\"abstract_t\">64</a>].</p><p class=\"headingAnchor\" id=\"H1060354714\"><span class=\"h2\">Surgical therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Surgical resection may be required as an adjunct to antimycobacterial therapy for children with MAC with isolated cavities, <em>M. abscessus</em>, failure to convert sputum cultures after six months, or patients who cannot tolerate antimycobacterial therapy [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"abstract_t\">2</a>]. (See <a href=\"#H1060354721\" class=\"local\">'Monitoring response to therapy'</a> below.)</p><p>In patients with limited pulmonary disease, surgical resection can be curative. In patients with extensive pulmonary disease, surgical resection may be performed in an attempt to decrease organism burden.</p><p class=\"headingAnchor\" id=\"H1060354721\"><span class=\"h2\">Monitoring response to therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Children who are being treated for pulmonary NTM disease should be monitored by monthly symptom screening, sputum analyses, and pulmonary function tests.</p><p>We do not routinely monitor response to therapy for pulmonary NTM disease with serial computed tomography of the chest, although repeat imaging may be warranted one to two months after initiation of therapy and for children who have clinical deterioration during therapy. Children with pulmonary NTM disease, by virtue of their underlying medical conditions, are likely to have higher cumulative radiation exposure at baseline than children without such conditions [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/68\" class=\"abstract_t\">68</a>].</p><p>Successful treatment of patients with MAC pulmonary disease is indicated by clinical improvement within three to six months and negative sputum cultures within 12 months of initiation of therapy [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/55\" class=\"abstract_t\">55</a>]. Possible reasons for failure to respond within these timeframes include poor <span class=\"nowrap\">adherence/drug</span> intolerance, macrolide resistance, or anatomic limitations (eg, focal cystic or cavitary disease) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"abstract_t\">2</a>]. An alternative medication regimen or surgery may be warranted.</p><p>The endpoint of therapy for <em>M. abscessus</em> is symptomatic improvement and prevention of disease progression rather than microbiologic eradication. Microbiologic eradication is possible only with surgical resection of limited lung disease [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/36\" class=\"abstract_t\">36</a>]. (See <a href=\"#H1060354693\" class=\"local\">'M. abscessus'</a> above and <a href=\"#H1060354714\" class=\"local\">'Surgical therapy'</a> above.)</p><p class=\"headingAnchor\" id=\"H1762313163\"><span class=\"h2\">Monitoring adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The antimycobacterial agents that are used to treat NTM pulmonary infections often are difficult to tolerate and some have important toxicities. Important adverse effects include (but are not limited to) ototoxicity and nephrotoxicity with <a href=\"topic.htm?path=amikacin-pediatric-drug-information\" class=\"drug drug_pediatric\">amikacin</a> and <a href=\"topic.htm?path=streptomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">streptomycin</a>, optic neuropathy with <a href=\"topic.htm?path=ethambutol-pediatric-drug-information\" class=\"drug drug_pediatric\">ethambutol</a>, and hepatotoxicity with <a href=\"topic.htm?path=isoniazid-pediatric-drug-information\" class=\"drug drug_pediatric\">isoniazid</a>. The adverse effects of the agents used to treat NTM infections are discussed in greater detail separately. (See <a href=\"topic.htm?path=pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity\" class=\"medical medical_review\">&quot;Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity&quot;</a> and <a href=\"topic.htm?path=manifestations-of-and-risk-factors-for-aminoglycoside-nephrotoxicity\" class=\"medical medical_review\">&quot;Manifestations of and risk factors for aminoglycoside nephrotoxicity&quot;</a> and <a href=\"topic.htm?path=ethambutol-an-overview\" class=\"medical medical_review\">&quot;Ethambutol: An overview&quot;</a> and <a href=\"topic.htm?path=azithromycin-clarithromycin-and-telithromycin\" class=\"medical medical_review\">&quot;Azithromycin, clarithromycin, and telithromycin&quot;</a> and <a href=\"topic.htm?path=rifamycins-rifampin-rifabutin-rifapentine\" class=\"medical medical_review\">&quot;Rifamycins (rifampin, rifabutin, rifapentine)&quot;</a> and <a href=\"topic.htm?path=isoniazid-an-overview\" class=\"medical medical_review\">&quot;Isoniazid: An overview&quot;</a> and <a href=\"topic.htm?path=isoniazid-hepatotoxicity\" class=\"medical medical_review\">&quot;Isoniazid hepatotoxicity&quot;</a> and <a href=\"topic.htm?path=aminoglycosides#H27\" class=\"medical medical_review\">&quot;Aminoglycosides&quot;, section on 'Toxicity'</a>.)</p><p>Common adverse effects of antimycobacterial medications are provided in the table (<a href=\"image.htm?imageKey=PEDS%2F86161\" class=\"graphic graphic_table graphicRef86161 \">table 4</a>).</p><p>It may be challenging to determine which medication is responsible for a given reaction because treatment of pulmonary NTM requires multiple medications. The medical comorbidities of children predisposed to pulmonary NTM infection further complicate the issue. Children with comorbid medical conditions may require additional medications that can interact with antimycobacterial therapy [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/19\" class=\"abstract_t\">19</a>]. They also may have baseline hepatic or renal dysfunction, which may decrease medication tolerance.</p><p>Most adverse effects are monitored clinically by assessing the patient for symptoms (eg, dizziness, vomiting, etc). However, specific parameters should be monitored as follows [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"abstract_t\">2</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Azithromycin</a> or <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a> &ndash; Periodic alkaline phosphatase, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) during the first three months of therapy. Baseline electrocardiogram to evaluate for prolonged QT interval is suggested before the initiation of therapy.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=rifabutin-pediatric-drug-information\" class=\"drug drug_pediatric\">Rifabutin</a> &ndash; Periodic white blood cell counts.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=amikacin-pediatric-drug-information\" class=\"drug drug_pediatric\">Amikacin</a> &ndash; Periodic amikacin levels.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=cefoxitin-pediatric-drug-information\" class=\"drug drug_pediatric\">Cefoxitin</a> &ndash; Periodic blood counts.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>TMP-SMX &ndash; Periodic blood counts.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=linezolid-pediatric-drug-information\" class=\"drug drug_pediatric\">Linezolid</a> &ndash; Periodic blood counts and eye examinations by an ophthalmologist.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ethambutol-pediatric-drug-information\" class=\"drug drug_pediatric\">Ethambutol</a> &ndash; Periodic eye examinations by an ophthalmologist.</p><p/><p>For children receiving <a href=\"topic.htm?path=rifampin-rifampicin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifampin</a>, a macrolide, and <a href=\"topic.htm?path=ethambutol-pediatric-drug-information\" class=\"drug drug_pediatric\">ethambutol</a>, we suggest baseline laboratory evaluation as indicated above. Thereafter, the need for subsequent laboratory evaluation should be driven by symptoms <span class=\"nowrap\">and/or</span> examination findings; scheduled laboratory evaluation may not be needed unless patients are receiving other marrow-suppressive or potentially hepatotoxic medications.</p><p class=\"headingAnchor\" id=\"H1060355551\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nontuberculous mycobacterial (NTM) pulmonary disease in children usually affects patients with underlying lung disease, particularly cystic fibrosis. <em>Mycobacterium avium complex</em> (MAC) and <em>Mycobacterium abscessus</em> are the species most frequently isolated from children with NTM pulmonary disease. (See <a href=\"#H1060354637\" class=\"local\">'Risk factors'</a> above and <a href=\"#H1060354623\" class=\"local\">'Microbiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical features of NTM pulmonary disease are variable and nonspecific. Most patients have chronic or recurrent cough. Other findings may include increased sputum, dyspnea, hemoptysis, chest pain, abnormal auscultatory findings (eg, crackles, wheezing, stridor), fever, fatigue, and weight loss. (See <a href=\"#H1060354644\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Radiographic findings in NTM pulmonary disease include nodular or cavitary opacities on chest radiograph and multifocal bronchiectasis with multiple small nodules on high-resolution computed tomography (<a href=\"image.htm?imageKey=PEDS%2F86444\" class=\"graphic graphic_diagnosticimage graphicRef86444 \">image 1</a>). (See <a href=\"#H1060354651\" class=\"local\">'Radiographic features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diagnosis of NTM pulmonary disease requires a combination of clinical symptoms, compatible radiographic findings, isolation of NTM, and exclusion of other conditions in the differential diagnosis (<a href=\"image.htm?imageKey=ID%2F61404\" class=\"graphic graphic_table graphicRef61404 \">table 2</a>). (See <a href=\"#H1326135742\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It is particularly important to distinguish tuberculous from NTM pulmonary disease because they have different therapeutic and public health implications. Additional considerations in the differential diagnosis of NTM pulmonary disease include progression of primary pulmonary disease, other forms of nodular lung disease (<a href=\"image.htm?imageKey=ID%2F70568\" class=\"graphic graphic_table graphicRef70568 \">table 3</a>), and <em>Pneumocystis jirovecii</em> pneumonia. Microbiologic studies are necessary to distinguish among the possibilities. (See <a href=\"#H1060354665\" class=\"local\">'Differential diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antimycobacterial treatment generally is warranted for children who meet clinical and microbiologic criteria for NTM pulmonary disease (<a href=\"image.htm?imageKey=ID%2F61404\" class=\"graphic graphic_table graphicRef61404 \">table 2</a>). However, the potential risks and benefits of antimycobacterial therapy disease must be considered before initiating treatment. (See <a href=\"#H1762312992\" class=\"local\">'General principles'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For children in whom the distinction between NTM and <em>Mycobacterium tuberculosis</em> remains uncertain, we suggest empiric treatment with <a href=\"topic.htm?path=isoniazid-pediatric-drug-information\" class=\"drug drug_pediatric\">isoniazid</a>, <a href=\"topic.htm?path=rifampin-rifampicin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifampin</a>, <a href=\"topic.htm?path=ethambutol-pediatric-drug-information\" class=\"drug drug_pediatric\">ethambutol</a>, and a macrolide (<a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a> or <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a>) (<a href=\"image.htm?imageKey=PEDS%2F86161\" class=\"graphic graphic_table graphicRef86161 \">table 4</a>) pending speciation and results of antimycobacterial susceptibility testing (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H1326136013\" class=\"local\">'NTM and M. tuberculosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment of MAC pulmonary disease in children depends upon the severity.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For children with nodular or noncavitating bronchiectatic disease, we suggest treatment with a macrolide, a rifamycin, and <a href=\"topic.htm?path=ethambutol-pediatric-drug-information\" class=\"drug drug_pediatric\">ethambutol</a> (<a href=\"image.htm?imageKey=PEDS%2F86161\" class=\"graphic graphic_table graphicRef86161 \">table 4</a>) (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). Therapy is administered three times per week and continued until sputum cultures have been negative for at least one year.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For children with cavitary or extensive bronchiectatic disease, we suggest treatment with a macrolide, a rifamycin, <a href=\"topic.htm?path=ethambutol-pediatric-drug-information\" class=\"drug drug_pediatric\">ethambutol</a>, and an aminoglycoside (<a href=\"image.htm?imageKey=PEDS%2F86161\" class=\"graphic graphic_table graphicRef86161 \">table 4</a>) (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). Therapy is administered daily. The aminoglycoside is discontinued after eight weeks; the other drugs are continued until the child's sputum cultures have been negative for at least one year.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For children with <em>M. abscessus</em> pulmonary disease, we suggest initial treatment with a macrolide, <a href=\"topic.htm?path=amikacin-pediatric-drug-information\" class=\"drug drug_pediatric\">amikacin</a>, and either <a href=\"topic.htm?path=cefoxitin-pediatric-drug-information\" class=\"drug drug_pediatric\">cefoxitin</a> or a carbapenem (<a href=\"image.htm?imageKey=PEDS%2F86161\" class=\"graphic graphic_table graphicRef86161 \">table 4</a>) (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). The endpoint of therapy for <em>M. abscessus</em> is symptomatic improvement and prevention of disease progression rather than microbiologic eradication.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Surgical resection may be required as an adjunct to antimycobacterial therapy for children with MAC with isolated cavities,<em> M. abscessus</em>, failure to convert sputum cultures after six months, or patients who cannot tolerate antimycobacterial therapy. (See <a href=\"#H1060354714\" class=\"local\">'Surgical therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Children who are being treated for pulmonary NTM disease should be monitored by monthly symptom screening, sputum analyses, and pulmonary function tests. (See <a href=\"#H1060354721\" class=\"local\">'Monitoring response to therapy'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/1\" class=\"nounderline abstract_t\">Fraser L, Moore P, Kubba H. Atypical mycobacterial infection of the head and neck in children: a 5-year retrospective review. Otolaryngol Head Neck Surg 2008; 138:311.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/2\" class=\"nounderline abstract_t\">Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/3\" class=\"nounderline abstract_t\">Celdr&aacute;n A, Esteban J, Ma&ntilde;as J, Granizo JJ. Wound infections due to Mycobacterium fortuitum after polypropylene mesh inguinal hernia repair. J Hosp Infect 2007; 66:374.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/4\" class=\"nounderline abstract_t\">Ferguson DD, Gershman K, Jensen B, et al. Mycobacterium goodii infections associated with surgical implants at Colorado hospital. Emerg Infect Dis 2004; 10:1868.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/5\" class=\"nounderline abstract_t\">Al Soub H, Al Maslamani M, Al Khuwaiter J, et al. Myocardial abscess and bacteremia complicating Mycobacterium fortuitum pacemaker infection: case report and review of the literature. Pediatr Infect Dis J 2009; 28:1032.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/6\" class=\"nounderline abstract_t\">McNabb A, Eisler D, Adie K, et al. Assessment of partial sequencing of the 65-kilodalton heat shock protein gene (hsp65) for routine identification of Mycobacterium species isolated from clinical sources. J Clin Microbiol 2004; 42:3000.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/7\" class=\"nounderline abstract_t\">Tortoli E. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s. Clin Microbiol Rev 2003; 16:319.</a></li><li class=\"breakAll\">Mycobacterium. List of prokaryotic names with standing in nomenclature. www.bacterio.cict.fr/m/mycobacterium.html (Accessed on July 21, 2012).</li><li class=\"breakAll\">American Academy of Pediatrics. Diseases caused by nontuberculous mycobacteria. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.831.</li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/10\" class=\"nounderline abstract_t\">Winthrop KL, Albridge K, South D, et al. The clinical management and outcome of nail salon-acquired Mycobacterium fortuitum skin infection. Clin Infect Dis 2004; 38:38.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/11\" class=\"nounderline abstract_t\">Roux AL, Catherinot E, Ripoll F, et al. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in france. J Clin Microbiol 2009; 47:4124.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/12\" class=\"nounderline abstract_t\">Esther CR Jr, Henry MM, Molina PL, Leigh MW. Nontuberculous mycobacterial infection in young children with cystic fibrosis. Pediatr Pulmonol 2005; 40:39.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/13\" class=\"nounderline abstract_t\">Levy I, Grisaru-Soen G, Lerner-Geva L, et al. Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerg Infect Dis 2008; 14:378.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/14\" class=\"nounderline abstract_t\">Olivier KN, Weber DJ, Wallace RJ Jr, et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003; 167:828.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/15\" class=\"nounderline abstract_t\">Pierre-Audigier C, Ferroni A, Sermet-Gaudelus I, et al. Age-related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis. J Clin Microbiol 2005; 43:3467.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/16\" class=\"nounderline abstract_t\">Bryant JM, Grogono DM, Rodriguez-Rincon D, et al. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science 2016; 354:751.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/17\" class=\"nounderline abstract_t\">Cruz AT, Ong LT, Starke JR. Mycobacterial infections in Texas children: a 5-year case series. Pediatr Infect Dis J 2010; 29:772.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/18\" class=\"nounderline abstract_t\">Wolinsky E. Mycobacterial lymphadenitis in children: a prospective study of 105 nontuberculous cases with long-term follow-up. Clin Infect Dis 1995; 20:954.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/19\" class=\"nounderline abstract_t\">Chesney PJ. Nontuberculous mycobacteria. Pediatr Rev 2002; 23:300.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/20\" class=\"nounderline abstract_t\">Grange JM, Yates MD, Pozniak A. Bacteriologically confirmed non-tuberculous mycobacterial lymphadenitis in south east England: a recent increase in the number of cases. Arch Dis Child 1995; 72:516.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/21\" class=\"nounderline abstract_t\">Pham-Huy A, Robinson JL, Tapi&eacute;ro B, et al. Current trends in nontuberculous mycobacteria infections in Canadian children: A pediatric investigators collaborative network on infections in Canada (PICNIC) study. Paediatr Child Health 2010; 15:276.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/22\" class=\"nounderline abstract_t\">Vu TT, Daniel SJ, Quach C. Nontuberculous mycobacteria in children: a changing pattern. J Otolaryngol 2005; 34 Suppl 1:S40.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/23\" class=\"nounderline abstract_t\">Fauroux B, Delaisi B, Cl&eacute;ment A, et al. Mycobacterial lung disease in cystic fibrosis: a prospective study. Pediatr Infect Dis J 1997; 16:354.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/24\" class=\"nounderline abstract_t\">Whittaker LA, Teneback C. Atypical mycobacterial and fungal infections in cystic fibrosis. Semin Respir Crit Care Med 2009; 30:539.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/25\" class=\"nounderline abstract_t\">Holland SM. Interferon gamma, IL-12, IL-12R and STAT-1 immunodeficiency diseases: disorders of the interface of innate and adaptive immunity. Immunol Res 2007; 38:342.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/26\" class=\"nounderline abstract_t\">Marazzi MG, Chapgier A, Defilippi AC, et al. Disseminated Mycobacterium scrofulaceum infection in a child with interferon-gamma receptor 1 deficiency. Int J Infect Dis 2010; 14:e167.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/27\" class=\"nounderline abstract_t\">Tsolia MN, Chapgier A, Taprantzi P, et al. Disseminated nontuberculous mycobacterial infection in a child with interferon-gamma receptor 1 deficiency. Eur J Pediatr 2006; 165:458.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/28\" class=\"nounderline abstract_t\">Koscielniak E, de Boer T, Dupuis S, et al. Disseminated Mycobacterium peregrinum infection in a child with complete interferon-gamma receptor-1 deficiency. Pediatr Infect Dis J 2003; 22:378.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/29\" class=\"nounderline abstract_t\">Vesterhus P, Holland SM, Abrahamsen TG, Bjerknes R. Familial disseminated infection due to atypical mycobacteria with childhood onset. Clin Infect Dis 1998; 27:822.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/30\" class=\"nounderline abstract_t\">Colombo RE, Hill SC, Claypool RJ, et al. Familial clustering of pulmonary nontuberculous mycobacterial disease. Chest 2010; 137:629.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/31\" class=\"nounderline abstract_t\">Koh WJ, Kwon OJ, Kim EJ, et al. NRAMP1 gene polymorphism and susceptibility to nontuberculous mycobacterial lung diseases. Chest 2005; 128:94.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/32\" class=\"nounderline abstract_t\">Unal E, Yen C, Saiman L, et al. A low incidence of nontuberculous mycobacterial infections in pediatric hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2006; 12:1188.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/33\" class=\"nounderline abstract_t\">Wu UI, Holland SM. Host susceptibility to non-tuberculous mycobacterial infections. Lancet Infect Dis 2015; 15:968.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/34\" class=\"nounderline abstract_t\">Aronchick JM, Miller WT Jr. Disseminated nontuberculous mycobacterial infections in immunosuppressed patients. Semin Roentgenol 1993; 28:150.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/35\" class=\"nounderline abstract_t\">Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009; 58:1.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/36\" class=\"nounderline abstract_t\">Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis 1993; 147:1271.</a></li><li class=\"breakAll\">Tebruegge M, Curtis N. Mycobacterium nontuberculosis species. In: Principles and Practice of Pediatric Infectious Diseases, 5th ed, Long SS, Prober CG, Fischer M (Eds), Elsevier, Philadelphia 2018. p.806.</li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/38\" class=\"nounderline abstract_t\">Nolt D, Michaels MG, Wald ER. Intrathoracic disease from nontuberculous mycobacteria in children: two cases and a review of the literature. Pediatrics 2003; 112:e434.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/39\" class=\"nounderline abstract_t\">Esther CR Jr, Esserman DA, Gilligan P, et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010; 9:117.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/40\" class=\"nounderline abstract_t\">Freeman AF, Olivier KN, Rubio TT, et al. Intrathoracic nontuberculous mycobacterial infections in otherwise healthy children. Pediatr Pulmonol 2009; 44:1051.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/41\" class=\"nounderline abstract_t\">Kr&ouml;ner C, Griese M, Kappler M, et al. Endobronchial lesions caused by nontuberculous mycobacteria in apparently healthy pediatric patients. Pediatr Infect Dis J 2015; 34:532.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/42\" class=\"nounderline abstract_t\">Murillo J, Torres J, Bofill L, et al. Skin and wound infection by rapidly growing mycobacteria: an unexpected complication of liposuction and liposculpture. The Venezuelan Collaborative Infectious and Tropical Diseases Study Group. Arch Dermatol 2000; 136:1347.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/43\" class=\"nounderline abstract_t\">Somoskovi A, Mester J, Hale YM, et al. Laboratory diagnosis of nontuberculous mycobacteria. Clin Chest Med 2002; 23:585.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/44\" class=\"nounderline abstract_t\">Butler WR, Ahearn DG, Kilburn JO. High-performance liquid chromatography of mycolic acids as a tool in the identification of Corynebacterium, Nocardia, Rhodococcus, and Mycobacterium species. J Clin Microbiol 1986; 23:182.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/45\" class=\"nounderline abstract_t\">Keerthirathne TP, Magana-Arachchi DN, Madegedara D, Sooriyapathirana SS. Real time PCR for the rapid identification and drug susceptibility of Mycobacteria present in Bronchial washings. BMC Infect Dis 2016; 16:607.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/46\" class=\"nounderline abstract_t\">Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/47\" class=\"nounderline abstract_t\">Magis-Escurra C, Alffenaar JW, Hoefnagels I, et al. Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections. Int J Antimicrob Agents 2013; 42:256.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/48\" class=\"nounderline abstract_t\">Hafner R, Bethel J, Power M, et al. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. Antimicrob Agents Chemother 1998; 42:631.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/49\" class=\"nounderline abstract_t\">Waters V, Ratjen F. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Cochrane Database Syst Rev 2016; 12:CD010004.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/50\" class=\"nounderline abstract_t\">Griffith DE, Brown BA, Girard WM, et al. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 2001; 32:1547.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/51\" class=\"nounderline abstract_t\">Griffith DE, Brown BA, Murphy DT, et al. Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients. J Infect Dis 1998; 178:121.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/52\" class=\"nounderline abstract_t\">Griffith DE, Brown BA, Cegielski P, et al. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis 2000; 30:288.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/53\" class=\"nounderline abstract_t\">Kwak N, Park J, Kim E, et al. Treatment Outcomes of Mycobacterium avium Complex Lung Disease: A Systematic Review and Meta-analysis. Clin Infect Dis 2017.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/54\" class=\"nounderline abstract_t\">Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004; 38:1538.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/55\" class=\"nounderline abstract_t\">Wallace RJ Jr, Brown BA, Griffith DE, et al. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med 1996; 153:1766.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/56\" class=\"nounderline abstract_t\">Tanaka E, Kimoto T, Tsuyuguchi K, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1999; 160:866.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/57\" class=\"nounderline abstract_t\">Park J, Cho J, Lee CH, et al. Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense. Clin Infect Dis 2017; 64:301.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/58\" class=\"nounderline abstract_t\">Mougari F, Bouziane F, Crockett F, et al. Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies. Antimicrob Agents Chemother 2017; 61.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/59\" class=\"nounderline abstract_t\">Koh WJ, Jeong BH, Kim SY, et al. Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease. Clin Infect Dis 2017; 64:309.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/60\" class=\"nounderline abstract_t\">Shitrit D, Baum GL, Priess R, et al. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome. Chest 2006; 129:771.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/61\" class=\"nounderline abstract_t\">da Silva Telles MA, Chimara E, Ferrazoli L, Riley LW. Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates. J Med Microbiol 2005; 54:975.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/62\" class=\"nounderline abstract_t\">Guna R, Mu&ntilde;oz C, Dom&iacute;nguez V, et al. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii. J Antimicrob Chemother 2005; 55:950.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/63\" class=\"nounderline abstract_t\">Alcaide F, Calatayud L, Sant&iacute;n M, Mart&iacute;n R. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob Agents Chemother 2004; 48:4562.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/64\" class=\"nounderline abstract_t\">Pezzia W, Raleigh JW, Bailey MC, et al. Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin. Rev Infect Dis 1981; 3:1035.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/65\" class=\"nounderline abstract_t\">Ahn CH, Lowell JR, Ahn SS, et al. Chemotherapy for pulmonary disease due to Mycobacterium kansasii: efficacies of some individual drugs. Rev Infect Dis 1981; 3:1028.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/66\" class=\"nounderline abstract_t\">Ahn CH, Lowell JR, Ahn SS, et al. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. Am Rev Respir Dis 1983; 128:1048.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/67\" class=\"nounderline abstract_t\">Banks J, Hunter AM, Campbell IA, et al. Pulmonary infection with Mycobacterium kansasii in Wales, 1970-9: review of treatment and response. Thorax 1983; 38:271.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-pulmonary-infections-in-children/abstract/68\" class=\"nounderline abstract_t\">Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med 2007; 357:2277.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 85894 Version 16.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1060355551\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1060354616\" id=\"outline-link-H1060354616\">INTRODUCTION</a></li><li><a href=\"#H1060354623\" id=\"outline-link-H1060354623\">MICROBIOLOGY</a></li><li><a href=\"#H1060354630\" id=\"outline-link-H1060354630\">EPIDEMIOLOGY</a></li><li><a href=\"#H1060354637\" id=\"outline-link-H1060354637\">RISK FACTORS</a></li><li><a href=\"#H1060354644\" id=\"outline-link-H1060354644\">CLINICAL FEATURES</a></li><li><a href=\"#H1060354651\" id=\"outline-link-H1060354651\">RADIOGRAPHIC FEATURES</a></li><li><a href=\"#H1326135742\" id=\"outline-link-H1326135742\">DIAGNOSIS</a><ul><li><a href=\"#H1762312726\" id=\"outline-link-H1762312726\">Diagnostic criteria</a><ul><li><a href=\"#H1326135601\" id=\"outline-link-H1326135601\">- Clinical suspicion</a></li><li><a href=\"#H1923504671\" id=\"outline-link-H1923504671\">- Imaging studies</a></li><li><a href=\"#H1762312692\" id=\"outline-link-H1762312692\">- Microbiologic testing</a></li><li><a href=\"#H2118471755\" id=\"outline-link-H2118471755\">- Clinical significance</a></li></ul></li></ul></li><li><a href=\"#H1060354665\" id=\"outline-link-H1060354665\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H1060354672\" id=\"outline-link-H1060354672\">TREATMENT</a><ul><li><a href=\"#H1762312992\" id=\"outline-link-H1762312992\">General principles</a></li><li><a href=\"#H2118470656\" id=\"outline-link-H2118470656\">Antimycobacterial therapy</a><ul><li><a href=\"#H1326136013\" id=\"outline-link-H1326136013\">- NTM and M. tuberculosis</a></li><li><a href=\"#H1060354686\" id=\"outline-link-H1060354686\">- M. avium complex</a><ul><li><a href=\"#H1923504373\" id=\"outline-link-H1923504373\">HIV-negative children</a></li><li><a href=\"#H1923504380\" id=\"outline-link-H1923504380\">HIV-positive children</a></li></ul></li><li><a href=\"#H1060354693\" id=\"outline-link-H1060354693\">- M. abscessus</a></li><li><a href=\"#H1060354707\" id=\"outline-link-H1060354707\">- M. kansasii</a></li></ul></li><li><a href=\"#H1060354714\" id=\"outline-link-H1060354714\">Surgical therapy</a></li><li><a href=\"#H1060354721\" id=\"outline-link-H1060354721\">Monitoring response to therapy</a></li><li><a href=\"#H1762313163\" id=\"outline-link-H1762313163\">Monitoring adverse effects</a></li></ul></li><li><a href=\"#H1060355551\" id=\"outline-link-H1060355551\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PEDS/85894|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/86444\" class=\"graphic graphic_diagnosticimage\">- HRCT NTM lung disease</a></li></ul></li><li><div id=\"PEDS/85894|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/61936\" class=\"graphic graphic_table\">- Mycobacteria classification</a></li><li><a href=\"image.htm?imageKey=ID/61404\" class=\"graphic graphic_table\">- Criteria for NTM diagnosis</a></li><li><a href=\"image.htm?imageKey=ID/70568\" class=\"graphic graphic_table\">- Ddx miliary infiltrates on CXR</a></li><li><a href=\"image.htm?imageKey=PEDS/86161\" class=\"graphic graphic_table\">- Treatment NTM children</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=aminoglycosides\" class=\"medical medical_review\">Aminoglycosides</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=azithromycin-clarithromycin-and-telithromycin\" class=\"medical medical_review\">Azithromycin, clarithromycin, and telithromycin</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cystic-fibrosis-antibiotic-therapy-for-chronic-pulmonary-infection\" class=\"medical medical_review\">Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cystic-fibrosis-clinical-manifestations-of-pulmonary-disease\" class=\"medical medical_review\">Cystic fibrosis: Clinical manifestations of pulmonary disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cystic-fibrosis-overview-of-the-treatment-of-lung-disease\" class=\"medical medical_review\">Cystic fibrosis: Overview of the treatment of lung disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-nontuberculous-mycobacterial-infections-of-the-lungs-in-hiv-negative-patients\" class=\"medical medical_review\">Diagnosis of nontuberculous mycobacterial infections of the lungs in HIV-negative patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=disseminated-nontuberculous-mycobacterial-ntm-infections-and-ntm-bacteremia-in-children\" class=\"medical medical_review\">Disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-of-nontuberculous-mycobacterial-infections\" class=\"medical medical_review\">Epidemiology of nontuberculous mycobacterial infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-pneumocystis-pneumonia-in-hiv-uninfected-patients\" class=\"medical medical_review\">Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in HIV-uninfected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=ethambutol-an-overview\" class=\"medical medical_review\">Ethambutol: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=isoniazid-hepatotoxicity\" class=\"medical medical_review\">Isoniazid hepatotoxicity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=isoniazid-an-overview\" class=\"medical medical_review\">Isoniazid: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=manifestations-of-and-risk-factors-for-aminoglycoside-nephrotoxicity\" class=\"medical medical_review\">Manifestations of and risk factors for aminoglycoside nephrotoxicity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mendelian-susceptibility-to-mycobacterial-diseases-specific-defects\" class=\"medical medical_review\">Mendelian susceptibility to mycobacterial diseases: Specific defects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=microbiology-of-nontuberculous-mycobacteria\" class=\"medical medical_review\">Microbiology of nontuberculous mycobacteria</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nontuberculous-mycobacterial-lymphadenitis-in-children\" class=\"medical medical_review\">Nontuberculous mycobacterial lymphadenitis in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nontuberculous-mycobacterial-skin-and-soft-tissue-infections-in-children\" class=\"medical medical_review\">Nontuberculous mycobacterial skin and soft tissue infections in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity\" class=\"medical medical_review\">Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rifamycins-rifampin-rifabutin-rifapentine\" class=\"medical medical_review\">Rifamycins (rifampin, rifabutin, rifapentine)</a></li></ul></div></div>","javascript":null}